JP2008509949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509949A5 JP2008509949A5 JP2007526350A JP2007526350A JP2008509949A5 JP 2008509949 A5 JP2008509949 A5 JP 2008509949A5 JP 2007526350 A JP2007526350 A JP 2007526350A JP 2007526350 A JP2007526350 A JP 2007526350A JP 2008509949 A5 JP2008509949 A5 JP 2008509949A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- optionally
- cycloalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 238000007792 addition Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- -1 piperazinylcarbonyl Chemical group 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 claims 3
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 150000002829 nitrogen Chemical group 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 208000002474 Tinea Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000000394 mitotic effect Effects 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 206010071155 Autoimmune arthritis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010005098 Blastomycosis Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000003495 Coccidiosis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000007336 Cryptococcosis Diseases 0.000 claims 1
- 241000221204 Cryptococcus neoformans Species 0.000 claims 1
- 206010012504 Dermatophytosis Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241001460074 Microsporum distortum Species 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000233870 Pneumocystis Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 101710183160 Serine/threonine-protein kinase PLK1 Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 241000130764 Tinea Species 0.000 claims 1
- 206010061418 Zygomycosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000004988 autoimmune vasculitis Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000010225 mixed cell type cancer Diseases 0.000 claims 1
- 208000029638 mixed neoplasm Diseases 0.000 claims 1
- 201000007524 mucormycosis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 125000005592 polycycloalkyl group Polymers 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04019359 | 2004-08-14 | ||
| PCT/EP2005/008626 WO2006018185A2 (en) | 2004-08-14 | 2005-08-09 | Dihydropteridinones for the treatment of cancer diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012151593A Division JP2012211178A (ja) | 2004-08-14 | 2012-07-05 | 癌疾患の治療のためのジヒドロプテリジノン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509949A JP2008509949A (ja) | 2008-04-03 |
| JP2008509949A5 true JP2008509949A5 (enExample) | 2008-10-02 |
Family
ID=34926179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526350A Withdrawn JP2008509949A (ja) | 2004-08-14 | 2005-08-09 | 癌疾患の治療のためのジヒドロプテリジノン |
| JP2012151593A Pending JP2012211178A (ja) | 2004-08-14 | 2012-07-05 | 癌疾患の治療のためのジヒドロプテリジノン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012151593A Pending JP2012211178A (ja) | 2004-08-14 | 2012-07-05 | 癌疾患の治療のためのジヒドロプテリジノン |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20060074088A1 (enExample) |
| EP (3) | EP2409706A1 (enExample) |
| JP (2) | JP2008509949A (enExample) |
| KR (2) | KR101353990B1 (enExample) |
| CN (2) | CN104055778A (enExample) |
| AR (1) | AR050694A1 (enExample) |
| AU (1) | AU2005274387B2 (enExample) |
| BR (1) | BRPI0513977A (enExample) |
| CA (1) | CA2575787C (enExample) |
| ES (2) | ES2975234T3 (enExample) |
| IL (2) | IL181304A (enExample) |
| MX (2) | MX343697B (enExample) |
| NZ (1) | NZ553722A (enExample) |
| PL (1) | PL3560499T3 (enExample) |
| RU (1) | RU2406503C2 (enExample) |
| TW (1) | TWI360420B (enExample) |
| WO (1) | WO2006018185A2 (enExample) |
| ZA (1) | ZA200700281B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US7553639B2 (en) * | 2006-01-31 | 2009-06-30 | Elan Pharma International Limited | Alpha-synuclein kinase |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| MX2009004077A (es) | 2006-10-19 | 2009-05-05 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| CA2672612A1 (en) | 2006-12-14 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinase inhibitors |
| EP2185559A1 (en) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| NZ584760A (en) | 2007-09-25 | 2012-03-30 | Takeda Pharmaceutical | Polo-like kinase inhibitors |
| WO2009103010A2 (en) * | 2008-02-13 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Alpha-synuclein kinase |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| EP2356122B1 (en) | 2008-06-23 | 2019-03-20 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| US20100075973A1 (en) * | 2008-08-28 | 2010-03-25 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| JP2013515734A (ja) * | 2009-12-23 | 2013-05-09 | エラン ファーマシューティカルズ，インコーポレイテッド | ポロ様キナーゼの阻害薬としてのプテリジノン |
| WO2011101369A1 (en) | 2010-02-17 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| CA2801074A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| AR085406A1 (es) | 2011-02-25 | 2013-09-25 | Takeda Pharmaceutical | Oxazinopteridinas y oxazinopteridinonas n-sustituidas |
| US20130131069A1 (en) * | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| US20150031699A1 (en) * | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| UY35945A (es) | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | Derivados de azaindol |
| JP2017504650A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| US20160347750A1 (en) * | 2014-01-31 | 2016-12-01 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
| CN106793775B (zh) * | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
| JP2017526741A (ja) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| SG11201703414VA (en) | 2014-10-27 | 2017-05-30 | Tensha Therapeutics Inc | Bromodomain inhibitors |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1256419A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途 |
| PE20181287A1 (es) | 2015-09-11 | 2018-08-07 | Dana Farber Cancer Inst Inc | Ciano tienotriazolpirazinas y usos de las mismas |
| SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8303657A (nl) | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
| DE3537761A1 (de) * | 1985-10-24 | 1987-04-30 | Bayer Ag | Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure |
| ES2058527T3 (es) | 1988-06-16 | 1994-11-01 | Smith Kline French Lab | Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen. |
| FR2645152B1 (fr) | 1989-03-30 | 1991-05-31 | Lipha | 3h-pteridinones-4, procedes de preparation et medicaments les contenant |
| CA2029651C (en) | 1989-11-17 | 2000-06-06 | David D. Davey | Tricyclic pteridinones and a process for their preparation |
| US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| TW274550B (enExample) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| CO4410190A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| BR9609083A (pt) * | 1995-05-19 | 1999-02-02 | Novartis Ag | Processo para a hidrogenação catalítica de compostos nitro aromáticos |
| US5698556A (en) * | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| WO1998011893A1 (en) | 1996-09-23 | 1998-03-26 | Eli Lilly And Company | Olanzapine dihydrate d |
| NZ509297A (en) * | 1998-08-11 | 2003-11-28 | Pfizer Prod Inc | Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors |
| AU2623900A (en) | 1999-01-22 | 2000-08-07 | American Home Products Corporation | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| WO2001019825A1 (en) | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| KR20020075805A (ko) | 2000-03-06 | 2002-10-05 | 워너-램버트 캄파니 | 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제 |
| DE10018783A1 (de) | 2000-04-15 | 2001-10-25 | Fresenius Kabi De Gmbh | Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt |
| US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| DE10058119A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Pepinotan-Kit |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| NZ531928A (en) * | 2001-09-04 | 2005-10-28 | Boehringer Ingelheim Pharma | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| ES2293965T3 (es) * | 2001-12-14 | 2008-04-01 | Laboratoires Serono Sa | Metodo de inducir la ovulacion utilizando un modulador no polipeptidico de los niveles de camp. |
| JP2005538048A (ja) * | 2002-05-03 | 2005-12-15 | シエーリング アクチエンゲゼルシャフト | チアゾリジノン類、それらの生成及び医薬剤としての使用 |
| CA2493908A1 (en) | 2002-08-08 | 2004-02-19 | Smithkline Beecham Corporation | Thiophene compounds |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| MXPA05009068A (es) * | 2003-02-26 | 2005-10-19 | Boehringer Ingelheim Pharma | Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos. |
| ATE468859T1 (de) | 2003-03-26 | 2010-06-15 | Wyeth Llc | Immunogene zusammensetzung und verfahren |
| AU2004231342A1 (en) | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| CA2552540A1 (en) * | 2004-01-17 | 2005-07-28 | Boehringer Ingelheim International Gmbh | Use of substituted pteridines for the treatment of diseases of the respiratory tract |
| DE102004002557A1 (de) * | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| DE102004034623A1 (de) * | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| EP1632493A1 (de) | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006021547A1 (de) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
| JP2008510771A (ja) * | 2004-08-27 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用 |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| EP1915155A1 (en) * | 2005-08-03 | 2008-04-30 | Boehringer Ingelheim International GmbH | Dihydropteridinones in the treatment of respiratory diseases |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| EP1994002A1 (en) * | 2006-03-07 | 2008-11-26 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them |
| EP2185559A1 (en) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
-
2005
- 2005-07-25 US US11/188,926 patent/US20060074088A1/en not_active Abandoned
- 2005-08-09 PL PL19168693.0T patent/PL3560499T3/pl unknown
- 2005-08-09 KR KR1020137009370A patent/KR101353990B1/ko not_active Expired - Fee Related
- 2005-08-09 ES ES19168693T patent/ES2975234T3/es not_active Expired - Lifetime
- 2005-08-09 EP EP11185693A patent/EP2409706A1/en not_active Withdrawn
- 2005-08-09 EP EP05770942.0A patent/EP1778240B1/en not_active Expired - Lifetime
- 2005-08-09 CN CN201410065809.2A patent/CN104055778A/zh active Pending
- 2005-08-09 MX MX2012004012A patent/MX343697B/es unknown
- 2005-08-09 KR KR1020077005855A patent/KR101283378B1/ko not_active Expired - Fee Related
- 2005-08-09 CN CNA2005800277121A patent/CN101022809A/zh active Pending
- 2005-08-09 ES ES05770942T patent/ES2800308T3/es not_active Expired - Lifetime
- 2005-08-09 RU RU2007109109/15A patent/RU2406503C2/ru not_active IP Right Cessation
- 2005-08-09 EP EP19168693.0A patent/EP3560499B1/en not_active Expired - Lifetime
- 2005-08-09 MX MX2007001851A patent/MX2007001851A/es active IP Right Grant
- 2005-08-09 AU AU2005274387A patent/AU2005274387B2/en not_active Ceased
- 2005-08-09 JP JP2007526350A patent/JP2008509949A/ja not_active Withdrawn
- 2005-08-09 CA CA2575787A patent/CA2575787C/en not_active Expired - Fee Related
- 2005-08-09 WO PCT/EP2005/008626 patent/WO2006018185A2/en not_active Ceased
- 2005-08-09 BR BRPI0513977-5A patent/BRPI0513977A/pt not_active IP Right Cessation
- 2005-08-09 NZ NZ553722A patent/NZ553722A/en not_active IP Right Cessation
- 2005-08-12 AR ARP050103378A patent/AR050694A1/es unknown
- 2005-08-12 TW TW094127427A patent/TWI360420B/zh not_active IP Right Cessation
-
2007
- 2007-01-10 ZA ZA200700281A patent/ZA200700281B/xx unknown
- 2007-02-13 IL IL181304A patent/IL181304A/en not_active IP Right Cessation
-
2008
- 2008-05-15 US US12/120,740 patent/US8058270B2/en active Active
-
2012
- 2012-07-05 JP JP2012151593A patent/JP2012211178A/ja active Pending
-
2013
- 2013-08-07 IL IL227841A patent/IL227841A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509949A5 (enExample) | ||
| RU2007109109A (ru) | Дигидроптеридиноны, предназначенные для лечения раковых заболеваний | |
| JP2013519704A5 (enExample) | ||
| JP6227707B2 (ja) | Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| CN111741954B (zh) | 用作egfr抑制剂的新型苯并咪唑化合物及衍生物 | |
| CA3140467C (en) | Pyrrolopyrimidine compound and use thereof | |
| TWI839363B (zh) | 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物 | |
| EP4003345B1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CN114761411B (zh) | 作为erk抑制剂的螺环类化合物及其应用 | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2017528475A (ja) | Ｒａｆキナーゼ阻害剤としての化合物および組成物 | |
| KR102598246B1 (ko) | Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도 | |
| JP2019500357A (ja) | Ｂｔｋキナーゼ阻害剤の結晶形およびその製造方法 | |
| JP2014520108A5 (enExample) | ||
| RU2018103332A (ru) | Пиримидиновое соединение с конденсированными кольцами, его промежуточное соединение, способ получения, композиция и применение | |
| WO2020155931A1 (zh) | 一种jak抑制剂及其制备方法 | |
| CA2619897A1 (fr) | Nouveaux derives tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| WO2023143147A1 (zh) | 一种哒嗪并吡啶酮类化合物、其药物组合物及应用 | |
| EP2850076A1 (en) | Monocyclic heteroaryl cycloalkyldiamine derivatives | |
| JP2019512534A5 (enExample) | ||
| WO2022268119A1 (zh) | 亚磺酰亚胺类化合物及其应用 | |
| JP7340680B2 (ja) | Ｉｒａｋ４及びｂｔｋマルチターゲット阻害剤としてのオキサゾール化合物 | |
| RU2730007C2 (ru) | Новые производные диаминопиридина | |
| EA029519B1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ |